Cambridge Investment Research Advisors’s AtriCure ATRC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$477K	Buy	+17,045	New	+$480K	﹤0.01%	3004

Other funds holding ATRC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cambridge Investment Research Advisors's ATRC Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in AtriCure (ATRC) in Q2 2026: 17,045 shares worth $477K. The stake represents ﹤0.01% of the portfolio and ranks #3004 among its holdings.

251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

Cambridge Investment Research Advisors held 17,045 shares of AtriCure worth $477K as of Q2 2026.
AtriCure was a new Cambridge Investment Research Advisors position in Q2 2026.
AtriCure made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3004 holding.
251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.